Zobrazeno 1 - 10
of 32
pro vyhledávání: '"MacBeth KJ"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Cathelin S; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Sharon D; Oncology Discovery, AbbVie Inc., North Chicago, IL, USA., Subedi A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Cojocari D; Oncology Discovery, AbbVie Inc., North Chicago, IL, USA., Phillips DC; Oncology Discovery, AbbVie Inc., North Chicago, IL, USA., Leverson JD; Oncology Development, AbbVie Inc., North Chicago, IL, USA., MacBeth KJ; Bristol Myers Squibb, Summit, NJ, USA., Nicolay B; Agios Pharmaceuticals, Inc., Cambridge, MA, USA., Narayanaswamy R; Agios Pharmaceuticals, Inc., Cambridge, MA, USA., Ronseaux S; Agios Pharmaceuticals, Inc., Cambridge, MA, USA., Liu G; Agios Pharmaceuticals, Inc., Cambridge, MA, USA., Chan SM; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. steven.chan@uhnresearch.ca.
Publikováno v:
Leukemia [Leukemia] 2022 Mar; Vol. 36 (3), pp. 869-872. Date of Electronic Publication: 2021 Nov 06.
Autor:
MacBeth KJ; Bristol Myers Squibb, Princeton, NJ. Electronic address: kjmacbeth@gmail.com., Chopra VS; Bristol Myers Squibb, Princeton, NJ., Tang L; Bristol Myers Squibb, Princeton, NJ., Zheng B; Bristol Myers Squibb, Princeton, NJ., Avanzino B; Bristol Myers Squibb, Princeton, NJ., See WL; Bristol Myers Squibb, Princeton, NJ., Schwickart M; Bristol Myers Squibb, Princeton, NJ., Figueroa ME; Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL., Quek L; MRC Molecular Hematology Unit, WIMM University of Oxford, Oxford, UK., DiMartino JF; Bristol Myers Squibb, Princeton, NJ.
Publikováno v:
Experimental hematology [Exp Hematol] 2021 Jun; Vol. 98, pp. 47-52.e6. Date of Electronic Publication: 2021 Mar 29.
Autor:
Wang F; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Morita K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. cdinardo@mdanderson.org., Furudate K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Oral and Maxillofacial Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan., Tanaka T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yan Y; Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houstont, TX, USA., Patel KP; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., MacBeth KJ; Celgene Corporation, Summit, NJ, USA., Wu B; Agios Pharmaceuticals, Cambridge, MA, USA., Liu G; Agios Pharmaceuticals, Cambridge, MA, USA., Frattini M; Celgene Corporation, Summit, NJ, USA., Matthews JA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Little LD; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gumbs C; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Song X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Thompson EJ; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bhalla KN; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Andrew Futreal P; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. afutreal@mdanderson.org., Takahashi K; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ktakahashi@mdanderson.org.; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ktakahashi@mdanderson.org.
Publikováno v:
Nature communications [Nat Commun] 2021 May 10; Vol. 12 (1), pp. 2607. Date of Electronic Publication: 2021 May 10.
Autor:
Santini V; MDS UNIT, Hematology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy. valeria.santini@unifi.it., Fenaux P; Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France., Giagounidis A; Department of Oncology, Hematology, and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany., Platzbecker U; Medical Clinic and Policlinic I, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany., List AF; Formerly Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Haferlach T; MLL Munich Leukemia Laboratory, Munich, Germany., Zhong J; Bristol Myers Squibb, Princeton, NJ, USA., Wu C; Bristol Myers Squibb, Princeton, NJ, USA., Mavrommatis K; Bristol Myers Squibb, Princeton, NJ, USA., Beach CL; Bristol Myers Squibb, Princeton, NJ, USA., MacBeth KJ; Bristol Myers Squibb, Princeton, NJ, USA., Almeida A; Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
Publikováno v:
Leukemia [Leukemia] 2021 Mar; Vol. 35 (3), pp. 897-900. Date of Electronic Publication: 2020 Jul 13.
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
Autor:
Sallman DA; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., McLemore AF; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Aldrich AL; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Komrokji RS; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., McGraw KL; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Dhawan A; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Geyer S; Health Informatics Institute, University of South Florida, Tampa, FL., Hou HA; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Eksioglu EA; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Sullivan A; NanoString Technologies, Inc., Seattle, WA., Warren S; NanoString Technologies, Inc., Seattle, WA., MacBeth KJ; Celgene Corporation, San Francisco, CA., Meggendorfer M; MLL Munich Leukemia Laboratory, Munich, Germany., Haferlach T; MLL Munich Leukemia Laboratory, Munich, Germany., Boettcher S; Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland., Ebert BL; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA.; Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and., Al Ali NH; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Lancet JE; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Cleveland JL; Department of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Padron E; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., List AF; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Publikováno v:
Blood [Blood] 2020 Dec 10; Vol. 136 (24), pp. 2812-2823.
Autor:
Stein EM; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: steine@mskcc.org., Fathi AT; Massachusetts General Hospital Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., DiNardo CD; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pollyea DA; Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA., Roboz GJ; Weill Cornell Medical College, New York, NY, USA; New York Presbyterian Hospital, New York, NY, USA., Collins R; University of Texas Southwestern Medical Center, Dallas, TX, USA., Sekeres MA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Stone RM; Dana Farber Cancer Institute, Boston, MA, USA., Attar EC; Agios Pharmaceuticals, Cambridge, MA, USA., Frattini MG; Celgene, Summit, NJ, USA., Tosolini A; Celgene, Summit, NJ, USA., Xu Q; Celgene, Summit, NJ, USA., See WL; Celgene, Summit, NJ, USA., MacBeth KJ; Celgene, Summit, NJ, USA., de Botton S; Département d'Hématologie et Département d'Innovation Thérapeutique, Gustave Roussy, Villejuif, France; Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France., Tallman MS; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA., Kantarjian HM; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
The Lancet. Haematology [Lancet Haematol] 2020 Apr; Vol. 7 (4), pp. e309-e319. Date of Electronic Publication: 2020 Mar 05.